.
MergerLinks Header Logo

Announced

Completed

GlaxoSmithKline and Pfizer formed a £9.8bn joint venture.

Financials

Edit Data
Transaction Value£9,800m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Health Care Services

Friendly

Joint Venture

United Kingdom

consumer health

Private

Cross Border

Majority

Single Bidder

Completed

Synopsis

Edit

GlaxoSmithKline, a British pharmaceutical company, and Pfizer, an American pharmaceutical corporation, formed a £9.8bn joint venture to create a premier global consumer healthcare company with robust iconic brands. The deal announced is ending to a yearlong process by Pfizer to shed its consumer business, as it and other pharmaceutical companies focus more on higher-margin prescription-drugs. Glaxo has been pursuing the same focus, though has until now stayed committed to its consumer business, which its chief executive led before her promotion to the top job. Glaxo will hold a 68% stake and Pfizer the remaining 32% of the new joint venture, which generated combined sales of $12.7bn last year.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US